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Viral encephalitis and glioblastoma are both relatively rare conditions with poor
prognoses. While the clinical and radiographic presentations of these diseases are often
distinctly different, viral encephalitis can sometimes masquerade as glioblastoma. Rarely,
glioblastoma can also be misdiagnosed as viral encephalitis. In some cases where a
high-grade glioma was initially diagnosed as viral encephalitis, antiviral administration has
proven effective for relieving early symptoms. We present three cases in which patients
presented with symptoms and radiographic findings suggestive of viral encephalitis and
experienced dramatic clinical improvement following treatment with acyclovir, only to later
be diagnosed with glioblastoma in the region of suspected encephalitis and ultimately
succumb to tumor progression.
Keywords: glioblastoma, GBM, glioma, encephalitis, viral encephalitis, herpes simplex encephalitis, antiviral,
acyclovir
INTRODUCTION
Viral encephalitis characteristically presents with fever, headache, neurological deficits, and seizures
(1). Significant edema or hemorrhage of the temporal lobes as well as regions of hypodensity
by T1-weighted magnetic resonance imaging (MRI) are typical (2). Due to the condition’s
urgency and the fact that evidence of infection can remain absent from cerebrospinal fluid (CSF),
presumed herpes simplex encephalitis (HSE) is often treated empirically with acyclovir, a viral DNA
replication inhibitor.
While acyclovir is primarily used as a first line defense against herpes simplex virus 1 (HSV-1), it
has been shown to be broadly effective against various viruses of theHerpesviridae family, including
the β-herpesvirus human cytomegalovirus (HCMV) (3). The presence of HCMV particles in
glioblastoma (GBM) tumor tissue of immunocompetent patients was first reported by Cobbs
et al. (4). HCMV has since been found to have oncomodulatory properties, including the ability
to increase GBM malignancy and stemness both in vitro and in murine models, though the
virus’ presence in GBM has since been the subject of controversy, with multiple groups both
corroborating and contradicting its presence. This debate, as well as the myriad documented effects
of HCMV on GBM, are reviewed by Foster et al. (5). HCMV localization to glioblastoma cells
has been the basis for multiple successful clinical trials, including one showing improved overall
survival in glioblastoma patients treated with the antiviral valganciclovir (6, 7) as well as multiple
trials of anti-GBM immunotherapy targeting HCMV antigens (8–10).
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Glioblastoma has uncommonly been misdiagnosed as viral
encephalitis as a result of atypical clinical and radiographic
presentation. In this series, we describe three cases in which
patients with an initial diagnosis of HSE were treated with
acyclovir without steroids, after which all patients showed
subsequent symptomatic improvement and ultimately developed
a GBM at the site of suspected encephalitis, suggesting either
viral implication in the genesis or progression of these patients’
tumors or a therapeutic effect of acyclovir on the early signs and
symptoms of GBM.
BACKGROUND
Case 1
A 76 year-old male presented with a 3 week history of
lightheadedness, olfactory hallucinations, confusion, and
intermittent agitation. An MRI was performed, which
showed significant edema in the right anteromedial temporal
lobe and insula concerning for herpes encephalitis. An
electroencephalogram (EEG) revealed a few right frontal
sharp waves and diffuse slowing concerning for possible seizure
activity. Remarkable laboratory data included a sodium level of
125 mEq/L. CSF revealed a glucose of 62 mg/dL (normal 40–70
mg/dL), total protein of 71 mg/dL (normal 0–44 mg/dL), and
6,750 RBCs with 2 WBCs. CSF testing was negative for human
cytomegalovirus (HCMV), herpes simplex virus (HSV), and
varicella zoster virus (VZV) by polymerase chain reaction (PCR).
CSF was also negative for Coccidioides antibodies and cytology
for malignant cells.
The patient was started on intravenous (IV) acyclovir
for presumed herpes simplex encephalitis and concomitant
levetiracetam to mitigate seizure risk. His symptoms improved
significantly, and he was discharged on a 21-day course of
IV acyclovir. At follow up, roughly 15 days after admission,
his prior symptoms of lightheadedness, olfactory hallucinations,
confusion, and agitation had all resolved.
A repeat MRI was performed 3 months after symptom
onset, showing a ring enhancing lesion concerning for
glioblastoma. The patient underwent right temporal craniotomy
for resection of the lesion. Pathology was consistent with
glioblastoma.
Case 2
A 77 year-old male presented with headache, profound
confusion, aphasia, and MRI findings of a non-enhancing left
frontal lesion which was hyperintense on T2-weighted and
FLAIR images (Figures 1A,B). The MRI also revealed non-
enhancing lesions in the temporal lobes and corpus callosum. The
patient’s vital signs on admission were: BP 159/69mmHg, HR 105
bpm, RR 24, and a temperature of 37.3◦C. The patient presented
with left carotid bruit. He could not follow commands. His
past medical history was significant for hypertension, diabetes
Abbreviations: CSF, cerebrospinal fluid; CT, computed tomography; EEG,
electroencephalogram; GBM, glioblastoma; HCMV, human cytomegalovirus; HSE,
herpes simplex encephalitis; HSV, herpes simplex virus; IV, intravenous; MRI,
magnetic resonance imaging; PCR, polymerase chain reaction; T-reg, regulatory
T-cell; VZV, varicella zoster virus.
mellitus diagnosed 10 years previously, coronary artery disease,
and moderately differentiated prostatic adenocarcinoma status
post-prostatectomy 10 years previously. Remarkable laboratory
data included blood glucose 179 mg/dL and arterial blood gas
pH 7.37, pCO2 49, pO2 72, SaO2 94% on 2 L/min O2 by nasal
cannula.
A neurology consult suggested a possible diagnosis of GBM,
but biopsy was deferred due to lack of a ring enhancing lesion.
No CSF sample was taken, and IV acyclovir was initiated to
treat possible herpes simplex encephalitis. On post-admission
day 2, a left internal cerebral arteriogram was performed which
demonstrated normal left common, external and internal carotid
arteries and normal left anterior and middle cerebral arteries.
Acyclovir was administered for 4 weeks. Steroids were not given
at any point during the patient’s hospitalization. The patient
displayed remarkable clinical improvement over the next 2
weeks, with neurological function returning to baseline. MRIs
performed on post-admission days 7 and 14 showed decreased
edema but interval increase in the size of the focal enhancing
lesion along the left frontal lobe gray matter concerning for
glioblastoma (Figures 1C–F).
Approximately 3 weeks after his original hospitalization, the
patient was readmitted due to neurological deterioration.
A fourth MRI scan showed increased enhancement
of the left frontal lesion (Figures 1G,H). A fifth MRI,
performed ∼4 months after his original hospitalization,
demonstrated a bifrontal “butterfly glioma.” The tumor was
subsequently resected, and pathology confirmed a diagnosis of
glioblastoma.
Case 3
A 78-year-old male presented with severe confusion, receptive
aphasia, headache, and dizziness. MRI revealed hyperintensity
in the posterior medial left thalamus, bilateral hippocampi, and
the left precentral gyrus on T2 FLAIR imaging with no contrast
enhancement. Computerized tomography (CT) imaging showed
mild microvascular disease but no evidence of acute intracranial
process or stenosis. The patient’s vital signs upon admission were:
BP 103/65 mmHg, HR 64 bpm, RR 18, and a temperature of
36.9◦C. His medical history was significant for atrial fibrillation,
for which he was prescribed Xarelto but was non-compliant. EEG
did not indicate seizure. CSF cultures were negative for HSV and
VZV and revealed normal differentiated cell count. Remarkable
laboratory results included a CBC with elevated lymphocyte
levels of 3.89E9 cells and low creatinine levels of 0.73 mg/dL.
The patient was immediately started on IV acyclovir. No
steroids were administered at any point during his hospital stay.
The patient displayed clinical improvement and returned to
baseline neurological function over the following week.
An MRI performed 2 weeks post-admission revealed stable
asymmetric non-enhancing T2 FLAIR hyperintensity involving
the left thalamus and increased size of enhancing intra-
axial lesion in the left precentral gyrus with surrounding T2
FLAIR hyperintensity, concerning for a neoplastic process. The
patient was readmitted 3 months after his initial hospitalization
for resection of a brain mass which was determined to be
glioblastoma following biopsy.
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FIGURE 1 | FLAIR images (A,C,E,F) T1 post-gadolinium images (B,D,F,G) of the patient at increasing days post-admission (P.A. d) and after administration of IV
acyclovir (ACV d). Arrows in A, C, and E demonstrate decreasing FLAIR signal in the left frontal white matter from day 1 to day 17 of acyclovir administration. Double
arrows in (B,D,F) demonstrate decreasing left frontal sulcal effacement and increasing size of the left frontal enhancing lesion. Increasing FLAIR signal and increasing
size of the enhancing lesion on T1 post-gadolinium of the left frontal lobe are again noted on post-admission day 45 and post-acyclovir day 17 (G,H).
DISCUSSION
This report describes three cases of patients with compelling
clinical and radiographic evidence of HSE, despite two testing
negative by PCR of CSF for common encephalitis-related viruses
such as HSV and VZV. All were empirically started on IV
acyclovir, regained much or all of their baseline neurological
function, and two demonstrated radiographic improvement.
Following cessation of acyclovir administration, all three patients
experienced a relapse of neurological deterioration and eventual
development of glioblastoma at the site of presumed viral
encephalitis. Steroids were not administered to any patient
during their hospital stay, and no other drugs administered
during that period (e.g., levetiracetam) are known to resolve
edema.
These findings are consistent with nine other English-
language reports describing patients with symptoms of
HSE ultimately being diagnosed with GBM or gliomatosis
cerebri (11–16). Including the cases presented here, acyclovir
was administered empirically in 10 of 12 cases, with only
two receiving steroids during their initial hospital stays.
Of the ten cases in which acyclovir was administered
(Table 1), eight noted clinical improvement following antiviral
treatment.
Several possible mechanisms of disease are consistent with
the atypical progression of glioblastoma and symptomatic
responsiveness to acyclovir described in these cases. First, the
patients may have developed viral encephalitis and glioblastoma
in the same place coincidentally—an unlikely possibility given
the relative rarity of these diseases and the time course for their
discovery and progression. Alternatively, viral encephalitis could
have played a causative role in gliomagenesis. Though most
studies suggests that herpesviruses play an oncomodulatory,
rather than oncogenic, role in the progression of glioblastoma
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TABLE 1 | Cases of glioblastoma masquerading as viral encephalitis.
References Sex Age Temporal
lobe
involvement
CSF viral
PCR
CSF
abnormality*
Acyclovir
administered
Steroids
administered
Clinical
improvement
Radiographic
improvement
This study M 76 Yes Neg Yes Yes No Yes Unknown
M 77 Yes N/A Unknown Yes No Yes Yes
M 78 No Neg Yes Yes No Yes No
Rees and Howard
(11)
F 41 Yes Neg No Yes No Yes Unknown
M 49 Yes Neg No Yes No Yes Yes
F 72 Yes Neg No Yes No No Unknown
Nam et al. (12) M 70 Yes Neg Yes Yes Yes Yes Unknown
Wang and Luo (13) M 50 Yes Neg Yes Yes Yes Yes Yes
Smithson and
Larner (14)
M 48 Yes Neg No Yes No Yes Yes
Sun et al. (15) M 56 Yes Neg Yes Yes No No No
*Defined as one or more characteristics consistent with viral encephalitis, e.g., moderately elevated protein, elevated mononuclear cell count, and/or moderately decreased glucose.
(17–19), other groups have hypothesized that these viruses may
transform cells via a “hit and run” mechanism (20, 21).
One or more patients’ tumors may have instead acted as a
reservoir for latent infection, which upon reactivation resulted in
findings consistent with encephalitis. HCMV, known to latently
infect GBM tumors, increases the production of reactive oxygen
species and induces expression of cellular enzymes and growth
factors, including COX-2 andVEGF, that can contribute to tumor
invasion, angiogenesis, and vascular permeability (22). Viral
reactivation could therefore result in increased inflammation
and tumor malignancy. In this case, it is possible that acyclovir
inhibited HCMV-driven phenotypes of infected GBM cells,
leading to the observed resolution of initial symptoms.
Finally, glioblastoma may have simply masqueraded as viral
encephalitis and responded to treatment with antivirals. Previous
studies have shown acyclovir’s efficacy in inhibiting in vitro
growth of glioblastoma cells (23) in addition to its inhibitory
effects on regulatory T cells (T-regs) which would otherwise
assist glioblastoma in immune evasion (24). Thus, nascent
glioblastoma and its associated peritumoral edema may have
been responsive to antiviral therapy irrespective of tumor
infection. This recalls the non-specific antitumor effects of
cidofovir, another antiviral agent which introduces double-
stranded cellular DNA breaks leading to GBM oncolysis (25).
CLOSING REMARKS
Whether via their specific antiviral action or efficacy against
GBM directly, antivirals have emerged as a promising therapeutic
in the treatment of glioblastoma, though the efficacy of
acyclovir in mitigating the early symptoms of GBM tumor
progression has yet to be thoroughly studied. Taken in
combination with the known inhibitory effects of acyclovir
on GBM cells and T-regs, the clinical findings reported
here make a strong case for future explorations of adjuvant
therapy with acyclovir to treat symptoms of early glioblastoma
progression.
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